Physician profile
Jared Graves
NPI 1447919311
$4,190.87
in general payments reported to CMS, 2019-2025
29 companies · $1,922 in 2025
The $1,922 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $239 · 2024: $2,029 · 2025: $1,922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,171 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,170.65 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $488.03 | 2024-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $461.79 | 2023-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $459.01 | 2025 | Onpattro, Amvuttra |
| Novartis Pharmaceuticals Corporation | $434.02 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $395.36 | 2023-2025 | |
| Novo Nordisk INC | $248.12 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Scpharmaceuticals INC. | $234.22 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $192.54 | 2023-2025 | Eliquis, Camzyos |
| Pfizer INC. | $131.53 | 2024-2025 | |
| Edwards Lifesciences Corporation | $129.45 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biosense Webster, INC. | $127.20 | 2024 | Carto 3 |
| Boston Scientific Corporation | $115.01 | 2025 | Watchman Flx |
| Amgen INC. | $108.24 | 2023-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $89.42 | 2023-2024 | Brilinta |
| Abiomed | $83.07 | 2024-2025 | Impella |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $82.16 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $66.83 | 2024-2025 | Lifevest |
| Otsuka America Pharmaceutical, INC. | $55.73 | 2023-2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $47.44 | 2024-2025 | Opsynvi, Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $39.89 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $38.60 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $31.82 | 2024-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $23.00 | 2025 | Assure Wcd |
| Medtronic, INC. | $22.10 | 2024 | Corevalve Evolut R |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.50 | 2024 | Caplyta |
| Vital Connect, INC | $20.90 | 2024 | Vitalpatch Rtm |
| Phathom Pharmaceuticals, INC. | $15.51 | 2024 | Voquezna |
| Baxter Healthcare | $14.28 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Abbvie INC. | $14.10 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.